These therapeutic agents inhibit VEGF from binding to its receptors (VEGFR-1 and VEGFR-2), thereby suppressing tumor angiogenesis, improving the tumor microenvironment, and enhancing chemotherapy drug delivery efficiency. The gene discussed is VEGFA; the disease is neoplasm.